Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henlius Denosumab Biosimilar Trial Enters Phase III

As Firm’s Shanghai Plant Has Received EU GMP Equivalence

Executive Summary

Henlius has administered the first dose in its international Phase III trial into its denosumab biosimilar candidate, HLX14. The firm has also revealed that its new Songjiang plant has been granted GMP equivalence with EU practices.

You may also be interested in...



Luye Claims A First With Chinese Denosumab Approval

Luye Pharma has claimed a world first after its Boan Biotech subsidiary obtained an approval from China’s NMPA for its Boyoubei denosumab biosimilar rival to Amgen’s Prolia.

Sandoz Delivers Denosumab Data As Biogen Sues On Tysabri

Having previously identified itself as the frontrunner in the race to launch a biosimilar to Amgen’s Prolia, Sandoz has now delivered positive confirmatory data, shortly after being sued in the US over its Polpharma-partnered proposed Tysabri biosimilar.

Lupin And DKSH To Market Five Alvotech Biosimilars In The Philippines

Lupin’s Multicare Pharmaceuticals subsidiary in the Philippines will partner with distributor DKSH to market five Alvotech biosimilars. Alvotech’s biosimilars, which remain at the pre-approval stages, reference Prolia/Xgeva, Eylea, Simponi, and two more undisclosed molecules. 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel